Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)RWD on T-DXd for gastric cancer in Japan

被引：0
|
作者：
Hisato Kawakami [1 ]
Koki Nakanishi [2 ]
Akitaka Makiyama [3 ]
Hirotaka Konishi [4 ]
Satoshi Morita [5 ]
Yukiya Narita [6 ]
Naotoshi Sugimoto [7 ]
Keiko Minashi [8 ]
Motohiro Imano [9 ]
Rin Inamoto [10 ]
Yasuhiro Kodera [2 ]
Hiroki Kume [11 ]
Keita Yamaguchi [11 ]
Wataru Hashimoto [12 ]
Kei Muro [6 ]
机构：
[1] Kindai University Faculty of Medicine,Department of Medical Oncology
[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery
[3] Gifu University Hospital,Cancer Center
[4] Kyoto Prefectural University of Medicine,Division of Digestive Surgery
[5] Kyoto University Graduate School of Medicine,Department of Biomedical Statistics and Bioinformatics
[6] Aichi Cancer Center Hospital,Department of Clinical Oncology
[7] Osaka International Cancer Institute,Department of Genetic Oncology
[8] Chiba Cancer Center,Division of Gastroenterology
[9] Kindai University Faculty of Medicine,Department of Surgery
[10] Saitama Cancer Center,Department of Gastroenterology
[11] Daiichi Sankyo Co. Ltd.,Oncology Medical Science Department I
[12] Daiichi Sankyo Co. Ltd.,Data Intelligence Department
来源：
Gastric Cancer | 2025年 / 28卷 / 1期
关键词：
Effectiveness; Gastric cancer; HER2-positive; Japan; Post-marketing surveillance; Real world; Safety; Third- or later-line; Trastuzumab-deruxtecan (T-DXd);
D O I：
10.1007/s10120-024-01555-w
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：51 / 61
页数：10
相关论文
共 50 条
  • [41] Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer
    Sung Yong Oh
    Suee Lee
    Seok Jae Huh
    Jeeyun Lee
    Seung Tae Kim
    Se Hoon Park
    Ho Yeong Lim
    Won Ki Kang
    Byung Woog Kang
    Jong Gwang Kim
    Hyo Jin Lee
    Jung Hoon Kim
    Jung Hun Kang
    HoUng Kim
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 501 - 508
  • [42] Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
    Kohei Shitara
    Kensei Yamaguchi
    Kei Muro
    Hisateru Yasui
    Daisuke Sakai
    Takashi Oshima
    Masahiro Fujimura
    Yuta Sato
    Shunsuke Yamazaki
    Tatsuya Wakabayashi
    Masahiro Sugihara
    Takahiro Kamio
    Hirokazu Shoji
    International Journal of Clinical Oncology, 2024, 29 : 27 - 35
  • [43] Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
    Shitara, Kohei
    Yamaguchi, Kensei
    Muro, Kei
    Yasui, Hisateru
    Sakai, Daisuke
    Oshima, Takashi
    Fujimura, Masahiro
    Sato, Yuta
    Yamazaki, Shunsuke
    Wakabayashi, Tatsuya
    Sugihara, Masahiro
    Kamio, Takahiro
    Shoji, Hirokazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (01) : 27 - 35
  • [44] Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer
    Oh, Sung Yong
    Lee, Suee
    Huh, Seok Jae
    Lee, Jeeyun
    Kim, Seung Tae
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    Kang, Byung Woog
    Kim, Jong Gwang
    Lee, Hyo Jin
    Kim, Jung Hoon
    Kang, Jung Hun
    Kim, HoUng
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) : 501 - 508
  • [45] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study
    Shitara, K.
    Seraj, J.
    Franke, F. A.
    Kawaguchi, Y.
    Shen, L.
    Kamio, T.
    Meinhardt, G.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1073 - S1073
  • [46] Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer
    Chang, Dwan-Ying
    Lin, Chia-Chi
    Chen, Tom Wei-Wu
    Lin, Ching-Hung
    Lee, Jih-Hsiang
    Chao, Ta-Chung
    Liu, Chun-Yu
    Achiwa, Issei
    Kamiyama, Emi
    Okuda, Yasuyuki
    Lee, Caleb
    Chao, Yee
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [47] Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Positive Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma Who Have Progressed On or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04, DG-04): A Randomized Phase 3 Study
    Shitara, Kohei
    Barlaskar, Ferdous
    Franke, Fabio A.
    Kawaguchi, Yoshinori
    Shen, Lin
    Kamio, Takahiro
    Meinhardt, Gerold
    Tabernero, Josep
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 95 - 95
  • [48] Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
    Ku, G. Y.
    Di Bartolomeo, M.
    Smyth, E.
    Chau, I.
    Park, H.
    Siena, S.
    Lonardi, S.
    Wainberg, Z. A.
    Ajani, J. A.
    Chao, J.
    Barlaskar, F.
    Kawaguchi, Y.
    Qin, A.
    Singh, J.
    Meinhardt, G.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1100 - S1100
  • [49] Co- occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial
    Janjigian, Y.
    Rha, S.
    Oh, D.
    Diez Garcia, M.
    van Laarhoven, H.
    Chao, Y.
    Di Bartolomeo, M.
    Mohammad, N. Haj
    Zhong, W.
    Croydon, E.
    Cecchi, F.
    Lee, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S358 - S359
  • [50] Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
    Kim, Tae-Hwan
    Do Cho, Hun
    Choi, Yong Won
    Lee, Hyun Woo
    Kang, Seok Yun
    Jeong, Geum Sook
    Choi, Jin-Hyuk
    Ahn, Mi Sun
    Sheen, Seung-Soo
    BMC CANCER, 2021, 21 (01)
12345